PE20211195A1 - A METHOD TO MODIFY THE RELEASE OF A THERAPEUTICALLY ACTIVE AGENT FROM AN ELASTOMERIC MATRIX - Google Patents
A METHOD TO MODIFY THE RELEASE OF A THERAPEUTICALLY ACTIVE AGENT FROM AN ELASTOMERIC MATRIXInfo
- Publication number
- PE20211195A1 PE20211195A1 PE2020000735A PE2020000735A PE20211195A1 PE 20211195 A1 PE20211195 A1 PE 20211195A1 PE 2020000735 A PE2020000735 A PE 2020000735A PE 2020000735 A PE2020000735 A PE 2020000735A PE 20211195 A1 PE20211195 A1 PE 20211195A1
- Authority
- PE
- Peru
- Prior art keywords
- core
- pyycomethycene
- therapeutically active
- active agent
- elastomeric matrix
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Abstract
SE REFIERE A UN METODO PARA MODIFICAR LA LIBERACION DE UN AGENTE TERAPEUTICAMENTE ACTIVO DE UNA MATRIZ ELASTOMERICA, EL CUAL COMPRENDE: A) PROPORCIONAR UN NUCLEO QUE COMPRENDE UNA MATRIZ ELASTOMERICA Y UN AGENTE TERAPEUTICAMENTE ACTIVO TAL COMO INDOMETACINA, DICLOFENACO, PIROXICAM, MELOXICAM Y CETOPROFENO; B) SUMERGIR EL NUCLEO EN UNA SOLUCION DE RECUBRIMIENTO QUE COMPRENDE UN ELASTOMERO QUE CONTIENE 20-35% EN PESO DE UN AGENTE DE RELLENO TAL COMO SILICE, DIOXIDO DE TITANIO, SULFATO DE BARIO, CARBONO Y LAS MEZCLAS DE LOS MISMOS, CALCULADO DE LA CANTIDAD TOTAL DE AGENTE DE RELLENO Y ELASTOMERO; C) CURAR EL NUCLEO SUMERGIDO PARA PROPORCIONAR UN NUCLEO RECUBIERTO; DONDE EL ELASTOMERO COMPRENDIDO EN EL NUCLEO Y EL ELASTOMERO COMPRENDIDO EN LA SOLUCION DE RECUBRIMIENTO SE SELECCIONAN DE POLI(DIMETIL)SILOXANOS, POLIETILENO ACETATOS DE VINILO (EVA), POLIURETANOS (PU), POLIHIDROXIETIL-METACRILATOS (PHEMA) Y POLIMETIL-METACRILATOS (PMMA).IT REFERS TO A METHOD TO MODIFY THE RELEASE OF A THERAPEUTICALLY ACTIVE AGENT FROM AN ELASTOMERIC MATRIX, WHICH INCLUDES: A) PROVIDE A CORE THAT INCLUDES AN ELASTOMERIC MATRIX AND A THERAPEUTICALLY ACTIVE AGENT, PYYCOMETHYCENE, PYYCOMETHYCENE, SUCH AS INDICOMETHYCENE, PYYCOMETHYCENE, PYYCOMETHYCENE. B) IMMERSE THE CORE IN A COATING SOLUTION THAT INCLUDES AN ELASTOMER CONTAINING 20-35% BY WEIGHT OF A FILLING AGENT SUCH AS SILICA, TITANIUM DIOXIDE, BARIUM SULPHATE, CARBON AND THE MIXTURES OF THE SAME, CALCULATED TOTAL AMOUNT OF FILLING AGENT AND ELASTOMER; C) CURE THE SUBMERGED CORE TO PROVIDE A COATED CORE; WHERE THE ELASTOMER INCLUDED IN THE CORE AND THE ELASTOMER INCLUDED IN THE COATING SOLUTION ARE SELECTED FROM POLY (DIMETHYL) SILOXANES, POLYETHYLENE ACETATES OF VINYL (EVA), POLYURETHANES (PU), POLYHYDROCEMETHYL METHYL METHYL METHYL-PMMAXYL EYLETHYLS ).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17193367 | 2017-09-27 | ||
EP18167014 | 2018-04-12 | ||
PCT/EP2018/075331 WO2019063382A1 (en) | 2017-09-27 | 2018-09-19 | A method for modifying release of a therapeutically active agent from an elastomeric matrix |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211195A1 true PE20211195A1 (en) | 2021-07-01 |
Family
ID=63592747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020000735A PE20211195A1 (en) | 2017-09-27 | 2018-09-19 | A METHOD TO MODIFY THE RELEASE OF A THERAPEUTICALLY ACTIVE AGENT FROM AN ELASTOMERIC MATRIX |
Country Status (18)
Country | Link |
---|---|
US (1) | US11666552B2 (en) |
EP (1) | EP3687495A1 (en) |
JP (1) | JP7242648B2 (en) |
KR (1) | KR20200059224A (en) |
CN (1) | CN111148507B (en) |
AU (1) | AU2018340266A1 (en) |
BR (1) | BR112020005928A2 (en) |
CA (1) | CA3076768A1 (en) |
CL (1) | CL2020000778A1 (en) |
CO (1) | CO2020003454A2 (en) |
IL (1) | IL272878A (en) |
JO (1) | JOP20200067A1 (en) |
MX (1) | MX2020007323A (en) |
PE (1) | PE20211195A1 (en) |
SG (1) | SG11202001293SA (en) |
TW (1) | TW201919587A (en) |
UY (1) | UY37906A (en) |
WO (1) | WO2019063382A1 (en) |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1222897A (en) * | 1996-03-29 | 1999-07-14 | 盖里列奥公司 | Method of forming strippable polyimide coating for optical fiber |
US6063395A (en) * | 1998-11-12 | 2000-05-16 | Leiras Oy | Drug delivery device especially for the delivery of progestins and estrogens |
US6117442A (en) * | 1998-11-12 | 2000-09-12 | Leiras Oy | Drug delivery device, especially for the delivery of androgens |
AU2002210580A1 (en) | 2000-10-20 | 2002-04-29 | Leiras Oy | Drug delivery system |
US20020136573A1 (en) * | 2001-01-25 | 2002-09-26 | Xerox Corporation | Infrared curing of fluoroelastomer coatings formed over silicone rubber in a fuser member |
US20070043332A1 (en) * | 2003-07-10 | 2007-02-22 | Galen (Chemiclas) Liimited | Intravaginal drug delivery devices |
US7914841B2 (en) * | 2006-02-09 | 2011-03-29 | Cook Medical Technologies Llc | Inline application of coatings |
TW200927141A (en) * | 2007-11-22 | 2009-07-01 | Bayer Schering Pharma Oy | Vaginal delivery system |
EP2140860A1 (en) | 2008-07-03 | 2010-01-06 | Bayer Schering Pharma Oy | An improved method of contraception |
WO2011156648A1 (en) * | 2010-06-09 | 2011-12-15 | President And Fellows Of Harvard College | Method for producing films |
US9801831B2 (en) * | 2010-12-30 | 2017-10-31 | Nanyang Technological University | Device for controlled release of a bioactive agent |
KR20120135689A (en) * | 2011-06-07 | 2012-12-17 | (주) 태웅메디칼 | Manufacturing method for drug releasing stent coated with the coating agent and thereny coating agent for drug releasing stent |
WO2013036775A1 (en) * | 2011-09-09 | 2013-03-14 | Axxia Pharmaceuticals, Llc | Silicone coated implants |
US9434857B2 (en) * | 2011-11-15 | 2016-09-06 | Ethicon, Inc. | Rapid cure silicone lubricious coatings |
AR089765A1 (en) * | 2012-01-23 | 2014-09-17 | Bayer Oy | A SYSTEM FOR THE SUPPLY OF A PHARMACO |
US20140037964A1 (en) * | 2012-08-02 | 2014-02-06 | Haipeng Zheng | Optical Article Containing A Self-Healing Coating And Improved Initial Haze |
US20160262923A1 (en) | 2013-10-18 | 2016-09-15 | Bayer Oy | Intrauterine delivery system |
EP3247327B1 (en) | 2015-01-21 | 2019-08-07 | Bayer Oy | Drug delivery system comprising a non-steroidal anti-inflammatory (nsaid) and a progestogenic compound and methods for manufacturing |
EP3393452B1 (en) | 2015-12-21 | 2021-08-04 | Bayer Oy | Method for manufacturing a drug delivery device |
WO2018111943A1 (en) * | 2016-12-12 | 2018-06-21 | The Regents Of The University Of California | Implantable and non-invasive stimulators for gastrointestinal therapeutics |
-
2018
- 2018-09-19 WO PCT/EP2018/075331 patent/WO2019063382A1/en unknown
- 2018-09-19 KR KR1020207008324A patent/KR20200059224A/en not_active Application Discontinuation
- 2018-09-19 AU AU2018340266A patent/AU2018340266A1/en not_active Abandoned
- 2018-09-19 EP EP18770027.3A patent/EP3687495A1/en active Pending
- 2018-09-19 SG SG11202001293SA patent/SG11202001293SA/en unknown
- 2018-09-19 CA CA3076768A patent/CA3076768A1/en active Pending
- 2018-09-19 CN CN201880062728.3A patent/CN111148507B/en active Active
- 2018-09-19 PE PE2020000735A patent/PE20211195A1/en unknown
- 2018-09-19 JP JP2020517371A patent/JP7242648B2/en active Active
- 2018-09-19 BR BR112020005928-5A patent/BR112020005928A2/en unknown
- 2018-09-19 MX MX2020007323A patent/MX2020007323A/en unknown
- 2018-09-19 JO JOP/2020/0067A patent/JOP20200067A1/en unknown
- 2018-09-19 US US16/649,944 patent/US11666552B2/en active Active
- 2018-09-26 TW TW107133758A patent/TW201919587A/en unknown
- 2018-09-27 UY UY0001037906A patent/UY37906A/en not_active Application Discontinuation
-
2020
- 2020-02-24 IL IL272878A patent/IL272878A/en unknown
- 2020-03-25 CO CONC2020/0003454A patent/CO2020003454A2/en unknown
- 2020-03-25 CL CL2020000778A patent/CL2020000778A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN111148507A (en) | 2020-05-12 |
IL272878A (en) | 2020-04-30 |
CN111148507B (en) | 2023-09-26 |
JP2020535159A (en) | 2020-12-03 |
MX2020007323A (en) | 2020-09-07 |
EP3687495A1 (en) | 2020-08-05 |
SG11202001293SA (en) | 2020-03-30 |
TW201919587A (en) | 2019-06-01 |
US11666552B2 (en) | 2023-06-06 |
CA3076768A1 (en) | 2019-04-04 |
US20200276159A1 (en) | 2020-09-03 |
RU2020113426A3 (en) | 2022-02-22 |
BR112020005928A2 (en) | 2020-10-06 |
UY37906A (en) | 2019-02-28 |
WO2019063382A1 (en) | 2019-04-04 |
RU2020113426A (en) | 2021-10-27 |
CL2020000778A1 (en) | 2020-09-25 |
CO2020003454A2 (en) | 2020-04-13 |
JP7242648B2 (en) | 2023-03-20 |
AU2018340266A1 (en) | 2020-03-05 |
JOP20200067A1 (en) | 2020-04-27 |
KR20200059224A (en) | 2020-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018003480A2 (en) | A composition for oral care with a high water content comprising an acceptable oral carrier, zinc phosphate, stannous fluoride and an organic acid buffer system | |
MX2016012151A (en) | Thermally expandable compositions. | |
MX2017011184A (en) | Method for producing photochromic cured body. | |
AR097032A1 (en) | POLY HYDROGELS (ALQUENILAMIDA) -POLISACÁRIDO FOR THE TREATMENT OF UNDERGROUND FORMATIONS | |
AR095446A1 (en) | METHODS TO MAKE COMPOSITIONS OF POLYMERS IN THE PRESENCE OF ATMOSPHERIC OXYGEN | |
BR112017012663A2 (en) | sun care composition, skin tightening and sun care films, and method for protecting the skin from UV rays. | |
EP3259652A4 (en) | Performing dynamic power control of platform devices | |
CR20180228A (en) | ATTACHED THERAPY WITH 25-HYDROXY VITAMIN D AND ARTICLES THEREOF | |
AR085096A1 (en) | ALEURODE CONTROL | |
BR112015022625A2 (en) | microarrays for therapeutic agent delivery and methods of use | |
NI201000156A (en) | NOVEL HETEROCYCLIC COMPOUNDS AND USES OF THEM. | |
WO2013103533A3 (en) | Free radical polymerizable compositions comprising ionic silicones | |
PE20121790A1 (en) | CONTROLLED RELEASE COMPOSITIONS | |
CL2017002031A1 (en) | Nasal powder formulation for the treatment of hypoglycemia | |
BR112018009311A8 (en) | A method for treating a human subject suffering from persistent TMA associated with hematopoietic stem cell transplantation. | |
MX2018003725A (en) | Thermally expandable compositions comprising polysaccharide. | |
MX2019007781A (en) | Anti-dazzling uv curable coating composition, method of applying the same and substrate coated therewith. | |
CR20150543A (en) | METHOD OF TREATMENT OF PANCREAS AND LIVER FOR CONDITIONS BY TRANSPLANT OF MOTHER CELLS IN WALLS OF BILIAR CONDUCT | |
AR105350A1 (en) | CLEANING COMPOSITION WITH PROPELLENT | |
BR112017023722A2 (en) | curable film-forming composition, coated substrate and method for coating a substrate | |
CL2018003826A1 (en) | Use of a lignin fraction as an anti phytopathogenic agent and phytopathogenic compositions containing said agent. | |
AR090793A1 (en) | COATINGS FOR NAILS AND RELATED METHODS | |
AR095905A1 (en) | PROCESS FOR THE CROSSING OF ELASTOMERS | |
CL2021000113A1 (en) | Biological methods to control phytopathogenic fungi | |
BR112013007656A2 (en) | SILICONE INITIATOR COMPOSITION, ITS USES AND PRODUCTION METHOD |